| Revista: | Gaceta médica de México |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000459637 |
| ISSN: | 0016-3813 |
| Autores: | López Hernández, Juan C1 Vargas Cañas, Edwin S1 Estrada, S. Alexander2 Galnares Olalde, Javier2 |
| Instituciones: | 1Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Clínica de Enfermedades Neuromusculares, Ciudad de México. México 2Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Departamento de Neurología, Ciudad de México. México |
| Año: | 2023 |
| Periodo: | Jul-Ago |
| Volumen: | 159 |
| Número: | 4 |
| Paginación: | 322-328 |
| País: | México |
| Idioma: | Español |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en español | Antecedentes: Durante la pandemia de COVID-19 se ha reportado incremento de casos de síndrome de Guillain-Barré (SGB). Objetivo: Describir características clínicas y pronóstico de pacientes con SGB antes y durante la pandemia de COVID-19. Material y métodos: Cohorte prospectiva de pacientes con SGB estratificados en dos subgrupos: antes (2018-2019) y durante (2020-2021) la pandemia de COVID-19. Se registraron características clínicas, paraclínicas y defunciones. Se definió como buen pronóstico a la recuperación de la marcha independiente a los tres meses. Resultados: Se incluyeron 201 pacientes (123 durante la pandemia y 78 antes), 69 % del sexo masculino, edad de 45 ± 16 años, 2.5 % de muertes intrahospitalarias. Durante la pandemia se observó mayor frecuencia de la variante desmielinizante (50 %), afección de nervios craneales bulbares (44 % versus 28 %), antecedente de vacunación (16 % versus 0 %) y menor puntuación en la escala MRC (30 ± 16.7 versus 34.3 ± 17.7); se observó aumento de casos de julio a septiembre (38 versus 13). No existieron diferencias significativas en la recuperación de la marcha independiente y número de defunciones. Conclusiones: Durante la pandemia se atendió mayor número de casos de SGB, 16 % asociado a la vacuna contra SARS-CoV-2; los pacientes no presentaron peor pronóstico |
| Resumen en inglés | Background: During the COVID-19 pandemic, an increase in the number of Guillain-Barre syndrome (GBS) cases has been reported. Objective: To describe the clinical characteristics and prognosis of patients with GBS before and during the COVID-19 pandemic. Material and methods: Prospective cohort of GBS patients divided in two subgroups: before (2018-2019) and during (2020-2021) the COVID-19 pandemic. Clinical and paraclinical characteristics, as well as deaths, were recorded. A good prognosis was defined as independent ambulation recovery at three months. Results: Two-hundred and one patients were included (123 during and 78 before the pandemic), out of whom 69 % were males; age was 45 ± 16 years, and there was 2.5 % of in-hospital deaths. During the pandemic, a higher frequency of the demyelinating variant (50 %), bulbar cranial nerves involvement (44 % vs. 28 %), prior history of vaccination (16 % vs. 0 %), and a lower MRC score (30 ± 16.7 vs. 34.3 ± 17.7) were documented. An increase in the number of cases was observed from July to September (38 vs. 13). There were no significant differences in independent ambulation recovery or in the number of deaths. Conclusions: During the COVID-19 pandemic, a higher number of GBS cases were treated, out of which 16 % were associated with the SARS-CoV-2 vaccine; patients treated during the pandemic did not have a worse prognosis |
| Disciplinas: | Medicina |
| Palabras clave: | Neurología, Neumología, Vacunas, Prevalencia, SARS-CoV-2, COVID-19, Síndrome de Guillain-Barré |
| Keyword: | Neurology, Pneumology, Vaccines, Prevalence, SARS-CoV-2, COVID-19, Guillain-Barre syndrome |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
